Skip to main content

Advertisement

SpringerLink
Log in

miR-188-5p and Host MALAT1 Regulate RBE Cell Migration, Invasion, and Apoptosis via Up-regulating PSMD10 in Cholangiocarcinoma

  • Original Article
  • Published:
Applied Biochemistry and Biotechnology Aims and scope Submit manuscript

Abstract

The study is designed to explore the regulatory network that MALAT1 competitively binds with miR-188-5p to up-regulate PSMD10 to facilitate cholangiocarcinoma cell migration and invasion and suppress apoptosis. qRT-PCR and fluorescence in situ hybridization (FISH) were used to examine the expression and positive signal of MALAT1 and miR-188-5p in cholangiocarcinoma tissues and HIBEC, HCCC-9810, RBE, and QBC939 cells. Western blot, qRT-PCR, and immunohistochemistry were selected to detect PSMD10 expression in cholangiocarcinoma tissues and cell lines. Dual luciferase reporter gene assay was adopted to verify that miR-188-5p targeted MALAT1 and PSMD10. qRT-PCR, pull down, and western blot were used to examine the regulation of MALAT1-miR-188-5p-PSMD10 axis. Transwell, wound healing assay, and Tunel cell apoptosis were adopted to respectively detect the regulatory abilities of MALAT1-miR-188-5p-PSMD10 axis on cell invasion, migration, and apoptosis. Western blot was used to detect the regulation mechanism of MALAT1 on Bax, Bcl-2, and caspase-3 proteins. Nude mice subcutaneous xenograft model of cholangiocarcinoma was established to examine the impacts of MALAT1 on subcutaneous tumor growth. Immunohistochemistry was adopted to examine the positive indicator of Ki67 antibodies and SMD10 antibodies in each group. MALAT1 and PSMD10 were highly expressed in cholangiocarcinoma tissues and cell lines, while miR-188-5p was lowly expressed. MALAT1 could competitively bind to miR-188-5p, and miR-188-5p could negatively regulate PSMD10. MALAT1, In-miR-188-5p, and PSMD10 could facilitate cell invasion and migration and inhibit apoptosis, while siMALAT1, miR-188-5p, and siPSMD10 produced an opposite result. MALAT1-miR-188-5p-PSMD10 axis could promote RBE cell invasion and migration and inhibit apoptosis, whereas siMALAT1-In-miR-188-5p-siPSMD10 axis showed an opposite result. On the other hand, it was verified that up-regulation/down-regulation of MALAT1 can inhibit/promote Bax and caspase-3 proteins and promote/inhibit the expression of Bcl-2 protein. MALAT1 could facilitate subcutaneous tumor growth and enhance cell proliferation and positive signal of PSMD10, while miR-188-5p worked in an opposite direction. MALAT1 competitively binds to miR-188-5p to up-regulate mRNA translation and protein expression of PSMD10, thereby facilitating cholangiocarcinoma cell invasion and migration and inhibiting its apoptosis. However, interfering MALAT1-miR-188-5p-PSMD10 axis could inhibit the occurrence and development of cholangiocarcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

Data Availability

The data and materials in the current study are available from the corresponding author on reasonable request.

References

  1. Razumilava, N., & Gores, G. J. (2014). Cholangiocarcinoma. Lancet, 383(9935), 2168–79.

    Article  Google Scholar 

  2. El-Diwany, R., Pawlik, T. M., & Ejaz, A. (2019). Intrahepatic cholangiocarcinoma. Surgical Oncology Clinics of North America, 28(4), 587–599.

    Article  Google Scholar 

  3. Waseem, D., & Tushar, P. (2017). Intrahepatic, perihilar and distal cholangiocarcinoma: Management and outcomes. Annals of Hepatology, 16(1), 133–139.

    Article  Google Scholar 

  4. Rizvi, S., Khan, S. A., Hallemeier, C. L., Kelley, R. K., & Gores, G. J. (2018). Cholangiocarcinoma - Evolving concepts and therapeutic strategies. Nature Reviews. Clinical Oncology, 15(2), 95–111.

    Article  CAS  Google Scholar 

  5. Banales, J. M., Marin, J., Lamarca, A., et al. (2020). Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Reviews. Gastroenterology & Hepatology, 17(9), 557–588.

    Article  Google Scholar 

  6. Blechacz, B. (2017). Cholangiocarcinoma: Current knowledge and new developments. Gut Liver, 11(1), 13–26.

    Article  Google Scholar 

  7. Qian, X., Zhao, J., Yeung, P. Y., Zhang, Q. C., & Kwok, C. K. (2019). Revealing lncRNA structures and interactions by sequencing-based approaches. Trends in Biochemical Sciences, 44(1), 33–52.

    Article  CAS  Google Scholar 

  8. Hao, W. Y., Guo, L. W., Luo, J., Shao, G. L., & Zheng, J. P. (2020). LncRNA TUG1 promotes growth and metastasis of cholangiocarcinoma cells by inhibiting miR-29a. Cancer Management and Research, 12, 11103–11111.

    Article  CAS  Google Scholar 

  9. Yu, A., Zhao, L., Kang, Q., Li, J., Chen, K., & Fu, H. (2020). Transcription factor HIF1α promotes proliferation, migration, and invasion of cholangiocarcinoma via long noncoding RNA H19/microRNA-612/Bcl-2 axis. Translational Research, 224, 26–39.

    Article  CAS  Google Scholar 

  10. Hrdlickova, R., Toloue, M., & Tian, B. (2017). RNA-Seq methods for transcriptome analysis. Wiley Interdisciplinary Reviews: RNA, 8(1). https://doi.org/10.1002/wrna.1364

  11. Goyal, B., Yadav, S., Awasthee, N., Gupta, S., Kunnumakkara, A. B., & Gupta, S. C. (2021). Diagnostic, prognostic, and therapeutic significance of long non-coding RNA MALAT1 in cancer. Biochimica et Biophysica Acta, Reviews on Cancer, 1875(2), 188502.

    Article  CAS  Google Scholar 

  12. Huang, X. J., Xia, Y., He, G. F., et al. (2018). MALAT1 promotes angiogenesis of breast cancer. Oncology Reports, 40(5), 2683–2689.

    CAS  Google Scholar 

  13. Dai, J., Zhou, N., Wu, R., et al. (2021). LncRNA MALAT1 Regulating lung carcinoma progression via the miR-491-5p/UBE2C axis. Pathology Oncology Research, 27, 610159.

    Article  Google Scholar 

  14. Malakar, P., Shilo, A., Mogilevsky, A., et al. (2017). Long noncoding RNA MALAT1 promotes hepatocellular carcinoma development by SRSF1 upregulation and mTOR activation. Cancer Research, 77(5), 1155–1167.

    Article  CAS  Google Scholar 

  15. Lu, T. X., & Rothenberg, M. E. (2018). MicroRNA. The Journal of Allergy and Clinical Immunology, 141(4), 1202–1207.

    Article  CAS  Google Scholar 

  16. Mohr, A. M., & Mott, J. L. (2015). Overview of microRNA biology. Seminars in Liver Disease, 35(1), 3–11.

    Article  CAS  Google Scholar 

  17. Kabekkodu, S. P., Shukla, V., Varghese, V. K., et al. (2018). Clustered miRNAs and their role in biological functions and diseases. Biological Reviews of the Cambridge Philosophical Society, 93(4), 1955–1986.

    Article  Google Scholar 

  18. Ala, U. (2020). Competing endogenous RNAs, non-coding RNAs and diseases: An intertwined story. Cells, 9(7), 1574.

  19. Zhang, L., Tao, H., Li, J., Zhang, E., Liang, H., & Zhang, B. (2021). Comprehensive analysis of the competing endogenous circRNA-lncRNA-miRNA-mRNA network and identification of a novel potential biomarker for hepatocellular carcinoma. Aging (Albany NY)., 13(12), 15990–16008.

    Article  CAS  Google Scholar 

  20. Liu, H., Chi, Z., Jin, H., & Yang, W. (2021). MicroRNA miR-188-5p as a mediator of long non-coding RNA MALAT1 regulates cell proliferation and apoptosis in multiple myeloma. Bioengineered., 12(1), 1611–1626.

    Article  Google Scholar 

  21. Fang, F., Chang, R. M., Yu, L., et al. (2015). MicroRNA-188-5p suppresses tumor cell proliferation and metastasis by directly targeting FGF5 in hepatocellular carcinoma. J Hepatol., 63(4), 874–85.

    Article  CAS  Google Scholar 

  22. Peng, Y., Shen, X., Jiang, H., et al. (2018). miR-188-5p suppresses gastric cancer cell proliferation and invasion via targeting ZFP91. Oncol Res., 27(1), 65–71.

    Article  Google Scholar 

  23. M. G. M. S., Chikhale, R., Nanaware, P. P., Dalvi, S., Venkatraman, P. (2022). A druggable pocket on PSMD10(Gankyrin) that can accommodate an interface peptide and doxorubicin. European Journal of Pharmacology, 915, 174718.

  24. Xiao, K., Ma, S., Xu, L., et al. (2021). Interaction between PSMD10 and GRP78 accelerates endoplasmic reticulum stress-mediated hepatic apoptosis induced by homocysteine. Gut Pathogens, 13(1), 63.

    Article  CAS  Google Scholar 

  25. Li, J., Tian, F., Li, D., et al. (2014). MiR-605 represses PSMD10/Gankyrin and inhibits intrahepatic cholangiocarcinoma cell progression. FEBS Letters, 588(18), 3491–500.

    Article  CAS  Google Scholar 

  26. Zheng, T., Hong, X., Wang, J., et al. (2014). Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma. Hepatology, 59(3), 935–46.

    Article  CAS  Google Scholar 

  27. Li, Z. X., Zhu, Q. N., Zhang, H. B., Hu, Y., Wang, G., & Zhu, Y. S. (2018). MALAT1: A potential biomarker in cancer. Cancer Management and Research, 10, 6757–6768.

    Article  CAS  Google Scholar 

  28. Sun, Y., & Ma, L. (2019). New insights into long non-coding RNA MALAT1 in cancer and metastasis. Cancers (Basel), 11(2), 216.

    Article  CAS  Google Scholar 

  29. Chen, W., Zhao, W., Chen, S., et al. (2018). Expression and correlation of MALAT1 and SOX9 in non-small cell lung cancer. The Clinical Respiratory Journal, 12(7), 2284–2291.

    Article  CAS  Google Scholar 

  30. Li, L., Chen, H., Gao, Y., et al. (2016). Long noncoding RNA MALAT1 promotes aggressive pancreatic cancer proliferation and metastasis via the stimulation of autophagy. Molecular Cancer Therapeutics, 15(9), 2232–43.

    Article  CAS  Google Scholar 

  31. Hao, T., Wang, Z., Yang, J., Zhang, Y., Shang, Y., & Sun, J. (2020). MALAT1 knockdown inhibits prostate cancer progression by regulating miR-140/BIRC6 axis. Biomedicine & Pharmacotherapy, 123, 109666.

    Article  CAS  Google Scholar 

  32. Li, C., Cui, Y., Liu, L. F., et al. (2017). High expression of long noncoding RNA MALAT1 indicates a poor prognosis and promotes clinical progression and metastasis in bladder cancer. Clinical Genitourinary Cancer, 15(5), 570–576.

    Article  Google Scholar 

  33. Ou, X., Gao, G., Bazhabayi, M., Zhang, K., Liu, F., & Xiao, X. (2019). MALAT1 and BACH1 are prognostic biomarkers for triple-negative breast cancer. Journal of Cancer Research and Therapeutics, 15(7), 1597–1602.

    Article  CAS  Google Scholar 

  34. Feng, C., Zhao, Y., Li, Y., Zhang, T., Ma, Y., & Liu, Y. (2019). LncRNA MALAT1 promotes lung cancer proliferation and gefitinib resistance by acting as a miR-200a sponge. Archivos de Bronconeumología, 55(12), 627–633.

    Article  Google Scholar 

  35. Amodio, N., Stamato, M. A., Juli, G., et al. (2018). Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. Leukemia, 32(9), 1948–1957.

    Article  CAS  Google Scholar 

  36. Zhang, X., Hong, R., Chen, W., Xu, M., & Wang, L. (2019). The role of long noncoding RNA in major human disease. Bioorganic Chemistry, 92, 103214.

    Article  CAS  Google Scholar 

  37. Han, T. S., Hur, K., Cho, H. S., & Ban, H. S. (2020). Epigenetic associations between lncRNA/circRNA and miRNA in hepatocellular carcinoma. Cancers (Basel), 12(9), 2622.

    Article  CAS  Google Scholar 

  38. Chi, Y., Wang, D., Wang, J., Yu, W., & Yang, J. (2019). Long non-coding RNA in the pathogenesis of cancers. Cells, 8(9), 1015.

    Article  CAS  Google Scholar 

  39. Zhou, R. S., Zhang, E. X., Sun, Q. F., et al. (2019). Integrated analysis of lncRNA-miRNA-mRNA ceRNA network in squamous cell carcinoma of tongue. BMC Cancer, 19(1), 779.

    Article  Google Scholar 

  40. Cardoso, A., Al-Eryani, L., & States, J. C. (2018). Arsenic-induced carcinogenesis: The impact of miRNA dysregulation. Toxicological Sciences, 165(2), 284–290.

    CAS  Google Scholar 

  41. Long, J., Bai, Y., Yang, X., et al. (2019). Construction and comprehensive analysis of a ceRNA network to reveal potential prognostic biomarkers for hepatocellular carcinoma. Cancer Cell International, 19, 90.

    Article  Google Scholar 

  42. Song, H., Sun, J., Kong, W., Ji, Y., Xu, D., & Wang, J. (2020). Construction of a circRNA-related ceRNA prognostic regulatory network in breast cancer. Oncotargets and Therapy, 13, 8347–8358.

    Article  CAS  Google Scholar 

  43. Yue, X., Wu, W. Y., Dong, M., & Guo, M. (2021). LncRNA MALAT1 promotes breast cancer progression and doxorubicin resistance via regulating miR-570-3p. Biomedical Journal, 44(6 Suppl 2), S296–S304.

    Article  CAS  Google Scholar 

  44. Wang, P., Bai, C., Shen, S., Jiang, C., Deng, J., & Han, D. (2021). MALAT1 promotes malignant pleural mesothelioma by sponging miR-141-3p. Open Medical (Wars), 16(1), 1653–1667.

    Article  CAS  Google Scholar 

  45. Wang, M., Zhang, H., Yang, F., et al. (2020). miR-188-5p suppresses cellular proliferation and migration via IL6ST: A potential noninvasive diagnostic biomarker for breast cancer. Journal of Cellular Physiology, 235(5), 4890–4901.

    Article  CAS  Google Scholar 

  46. Niu, H., Qu, A., & Guan, C. (2021). Suppression of MGAT3 expression and the epithelial-mesenchymal transition of lung cancer cells by miR-188-5p. Biomedical Journal, 44(6), 678–685.

    Article  CAS  Google Scholar 

  47. Li, X. L., Li, S. Z., Wu, C. X., & Xing, X. H. (2021). miR-188-5p inhibits proliferation, migration, and invasion in gallbladder carcinoma by targeting Wnt2b and Smad2. The Kaohsiung Journal of Medical Sciences, 37(4), 294–304.

    Article  CAS  Google Scholar 

  48. Zhu, J., Han, S. (2020). DARS-AS1 knockdown inhibits the growth of cervical cancer cells via downregulating HMGB1 via sponging miR-188-5p. Technology in Cancer Research & Treatment, 19, 1533033820971669.

Download references

Funding

This study was supported by the 2022 Hebei Medical Science Project Research Plan (no. 20221052).

Author information

Authors and Affiliations

  1. Department of Minimally Invasive and Biliary Surgery, The Second Hospital of Hebei Medical University, No. 215 Heping West Road, Shijiazhuang, 050000, Hebei, China

    Zhaoqiang Yin, Jianlong Wang, Tao Li, Lifeng Ma, Jiansheng Kang & Guochao Liu

Authors
  1. Zhaoqiang Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jianlong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tao Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lifeng Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jiansheng Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Guochao Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

ZY and GL conceived and designed the project. JW and TL acquired the data. LM and JK analyzed and interpreted the data. ZY and GL wrote the paper. All authors read and approved the manuscript.

Corresponding author

Correspondence to Guochao Liu.

Ethics declarations

Ethics Approval

All the study and specimen collection were approved by the Second Hospital of Hebei Medical University. The study has been carried out in accordance with the World Medical Association Declaration of Helsinki. All methods were carried out in accordance with relevant guidelines and regulations of the Basel Declaration. Our study is reported in accordance with ARRIVE guidelines.

Consent to Participate

Written informed consent was obtained from participants prior to the study.

Consent to Publish

Not applicable.

Competing Interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yin, Z., Wang, J., Li, T. et al. miR-188-5p and Host MALAT1 Regulate RBE Cell Migration, Invasion, and Apoptosis via Up-regulating PSMD10 in Cholangiocarcinoma. Appl Biochem Biotechnol 195, 655–671 (2023). https://doi.org/10.1007/s12010-022-04136-8

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12010-022-04136-8

Keywords

Search

Navigation